Every 8-K that Palisade Bio Inc (PALI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PALI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PALI filings page.
Palisade Bio reported second quarter 2026 results and progress on its lead IBD candidate PALI-2108. The company highlighted favorable Phase 1 safety, exposure and pharmacodynamic data, with all 5 ulcerative colitis patients showing clinical response and 2 achieving remission, and a roughly 47.5% mean SES-CD reduction in fibrostenotic Crohn’s disease patients.
PALI-2108 is advancing into Phase 2 trials: the ASCENTRA-UC study is expected to start in the second half of 2026 with primary efficacy results in the second half of 2027, and an IND for the ASCENTRA-CD Phase 2 trial is planned for the second half of 2026, with primary readout in early 2028. For the quarter ended June 30, 2026, Palisade reported $0.5 million in license revenue, research and development expenses of $7.4 million, general and administrative expenses of $4.8 million and a net loss of $10.6 million or $0.05 per share. Cash and cash equivalents were $125.2 million as of June 30, 2026, which the company believes will fund operations through the planned Phase 2 efficacy readouts.
Palisade Bio, Inc. held its 2026 annual stockholder meeting and made several governance and capital structure changes. Stockholders approved an amendment to increase authorized common stock from 300,000,000 to 450,000,000 shares, and total authorized capital stock from 307,000,000 to 457,000,000 shares, effective upon filing in Delaware.
The company’s stockholders also approved amended and restated 2021 equity incentive and employee stock purchase plans, non‑binding executive compensation, and equity awards for non‑employee directors. A new independent director, Jordan Zwick, was appointed to the Board and Audit Committee, with an initial restricted stock unit grant valued at $566,000 vesting over three years.
Palisade Bio reported first quarter 2026 results and highlighted progress of its lead IBD candidate, PALI-2108. The company completed Phase 1a/1b studies with favorable safety, target engagement in ileum and colon tissue, and early clinical activity, and is preparing Phase 2 trials in ulcerative colitis and Crohn’s disease starting in 3Q 2026 and 1Q 2027, respectively.
Research and development expenses rose to $6.4 million and general and administrative expenses to $4.4 million, driving a net loss of $9.6 million for the quarter. Palisade ended March 31, 2026 with $132.6 million in cash and cash equivalents and expects this to fund operations through Phase 2 efficacy readouts for PALI-2108 in 2027 and early 2028.
Palisade Bio, Inc. entered into a master services agreement with Iterative Scopes, Inc. d/b/a Iterative Health to help enroll patients in its planned Phase 2 study of PALI-2108 for moderate to severe ulcerative colitis. To support this collaboration, the company issued and sold 1,536,885 shares of common stock to an affiliate of Iterative Health for a total of $3.0 million, at $1.952 per share, which matches the average closing price over the five trading days before the closing date. The shares were sold in a private transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933.
Palisade Bio (PALI) reported a compensation plan change. The Board adopted a Phantom Unit Plan on September 4, 2025, and later approved its termination effective October 22, 2025.
Phantom Units granted under the plan to Chief Executive Officer J.D. Finley, Chief Medical Officer Mitchell Jones, and Senior Vice President of Finance Ryker Willie were unvested as of the termination date and will terminate for no consideration.
Palisade Bio reported results from its annual meeting. Stockholders approved an amendment allowing the board to implement a reverse stock split at a ratio of not less than 1-for-5 and not greater than 1-for-50, with the exact ratio set by the board and to be effected on or before December 31, 2025. Directors J.D. Finley, Donald Williams, and Emil Chuang were elected to serve until the 2026 annual meeting.
Shareholders also ratified Baker Tilly US, LLP as independent auditor for the fiscal year ending December 31, 2025. A quorum was reached with 3,585,700 shares present (approximately 39.32%) out of 9,119,152 shares outstanding as of the September 12, 2025 record date. Proposal 3, the reverse split authorization, received 2,353,265 votes for, 1,122,616 against, and 109,819 abstentions.
Palisade Bio, Inc. announced a corporate update and Nasdaq status. As of October 15, 2025, the company reported cash and cash equivalents of $133.3 million. Shares outstanding were 133,002,572 as of the same date, and the company had pre-funded warrants outstanding to purchase up to 73,271,424 shares of common stock.
On October 15, 2025, Palisade Bio received a minimum bid price compliance letter from Nasdaq confirming it has regained compliance with Listing Rule 5550(a)(2), closing the matter. The company had previously been notified on April 30, 2025 that its stock price was below the $1.00 minimum, with an initial cure period through October 27, 2025. The company noted there can be no assurance it will maintain compliance in the future.
Palisade Bio, Inc. filed a report explaining that it has canceled a previously scheduled special meeting of stockholders that was set to reconvene on October 10, 2025. The company also decided to withdraw from stockholder consideration the proposals that had been described in its definitive proxy statement filed on August 18, 2025.
The decision and related details were communicated through a press release issued on October 9, 2025, which is included as an exhibit to the report. This means stockholders will no longer vote on the withdrawn proposals at the canceled special meeting.
Palisade Bio, Inc. postponed its special meeting of stockholders because there were not enough shares of common stock represented in person or by proxy to reach a quorum. The meeting, originally convened on September 18, 2025, was adjourned and is scheduled to reconvene on September 26, 2025 at 10:00 a.m. Pacific Time.
The close of business on July 28, 2025 remains the record date, so only stockholders of record on that date are entitled to vote at the reconvened meeting. The proposals to be voted on are unchanged, and stockholders who already voted and do not wish to change their vote do not need to take any further action. Voting instructions are provided in the company’s definitive proxy statement on Schedule 14A and through the proxy voting platform.
Palisade Bio, Inc. filed an 8-K reporting executive change-in-control payment triggers tied to a Liquidity Change in Control and post-change termination events. The filing states that if an executive is terminated without cause or for good reason within 12 months following a Liquidity Change in Control, a severance payment becomes payable in a lump sum within 60 days. The same 60-day lump-sum timing is repeated for payments tied to the 7th anniversary of the Date of Grant and for amounts explicitly linked to the Liquidity Change in Control. The document is signed by J.D. Finley, Chief Executive Officer, and discloses timing and trigger mechanics but does not state specific payment amounts.